Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Documented diagnosis of non-small cell lung, pancreatic, colorectal cancer
Cachexia defined by Fearon criteria
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 12
Awards & highlights
PROACC-1 Trial Summary
This trial will test if a new drug is effective, safe, and tolerable for treating cancer-related cachexia and elevated GDF 15 levels.
Who is the study for?
This trial is for adults with non-small cell lung, pancreatic, or colorectal cancer who are experiencing cachexia (significant weight loss due to illness) as defined by Fearon criteria. They must have elevated GDF-15 protein levels and be able to consent to the study. People with tube feedings, other causes of cachexia, severe allergies to monoclonal antibodies, or poor kidney/liver function cannot join.Check my eligibility
What is being tested?
The trial is testing the effectiveness and safety of a drug called Ponsegromab in comparison to a placebo in patients suffering from cancer-related cachexia. Participants will either receive Ponsegromab or a placebo without knowing which one they're getting.See study design
What are the potential side effects?
Possible side effects of Ponsegromab may include allergic reactions similar to those seen with other monoclonal antibody therapies. Specific side effects are not listed but generally could range from mild infusion-related reactions to more serious organ-specific inflammation.
PROACC-1 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with lung, pancreatic, or colorectal cancer.
Select...
I have significant weight loss and muscle loss.
Select...
I have been diagnosed with lung, pancreatic, or colorectal cancer.
Select...
I am capable of limited self-care.
PROACC-1 Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 12
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 12
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change from baseline in body weight for ponsegromab compared to placebo
Secondary outcome measures
Change from baseline in anorexia/appetite; Nausea and vomiting; and Fatigue as measured by the Cancer Related Cachexia Symptom Diary (CRCSD)
Change from baseline in physical activity as measured with remote digital sensors
Electrocardiogram
+4 morePROACC-1 Trial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: Double-Blind ponsegromab Treatment medium dose followed by Open Label ponsegromab TreatmentExperimental Treatment1 Intervention
ponsegromab medium dose subcutaneous injection every 4 weeks
Group II: Double-Blind ponsegromab Treatment low dose followed by Open Label ponsegromab TreatmentExperimental Treatment1 Intervention
ponsegromab low dose subcutaneous injection every 4 weeks
Group III: Double-Blind ponsegromab Treatment high dose followed by Open Label ponsegromab TreatmentExperimental Treatment1 Intervention
ponsegromab high dose subcutaneous injection every 4 weeks
Group IV: Double-Blind Placebo Treatment followed by Open-Label ponsegromab TreatmentPlacebo Group1 Intervention
Match placebo subcutaneous injection every 4 weeks
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for colorectal cancer include chemotherapy, targeted therapy, and immunotherapy. Chemotherapy drugs like 5-fluorouracil (5-FU) and oxaliplatin work by interfering with DNA synthesis and cell division, leading to cancer cell death.
Targeted therapies, such as cetuximab and bevacizumab, inhibit specific molecules involved in tumor growth and angiogenesis, respectively. Cetuximab targets the epidermal growth factor receptor (EGFR), while bevacizumab targets vascular endothelial growth factor (VEGF).
Immunotherapy, including drugs like nivolumab, enhances the body's immune response against cancer cells by blocking inhibitory pathways like PD-1/PD-L1. These mechanisms are crucial for colorectal cancer patients as they offer multiple avenues to halt tumor progression and improve survival rates.
In the context of cachexia management, investigational treatments like Ponsegromab, which potentially neutralizes GDF 15, aim to address the severe weight loss and muscle wasting associated with advanced cancer, thereby improving patients' quality of life.
Metabolic reprogramming in epithelial ovarian cancer.
Metabolic reprogramming in epithelial ovarian cancer.
Find a Location
Who is running the clinical trial?
PfizerLead Sponsor
4,584 Previous Clinical Trials
14,635,478 Total Patients Enrolled
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,488 Previous Clinical Trials
11,812,319 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My weight loss is not due to cancer.I am currently on tube feedings or IV nutrition.My kidney or liver is not working properly.You have temporary reasons that are causing you to eat less.I have significant weight loss and muscle loss.I have been diagnosed with lung, pancreatic, or colorectal cancer.I am capable of limited self-care.I have been diagnosed with lung, pancreatic, or colorectal cancer.You have severe weight loss according to specific criteria called Fearon criteria.I'm sorry, I need more context to accurately provide a summary for this criterion. Could you please provide more information or context?
Research Study Groups:
This trial has the following groups:- Group 1: Double-Blind ponsegromab Treatment low dose followed by Open Label ponsegromab Treatment
- Group 2: Double-Blind Placebo Treatment followed by Open-Label ponsegromab Treatment
- Group 3: Double-Blind ponsegromab Treatment medium dose followed by Open Label ponsegromab Treatment
- Group 4: Double-Blind ponsegromab Treatment high dose followed by Open Label ponsegromab Treatment
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger